Prescription Drugs Resources

Evaluation of a Model Comparative Drug Price Resource in Fostering Prescriber - Patient Engagement, Lowering Consumer Costs and Improving Adherence

A majority of patients under age 65 face high and increasing out-of-pocket medication costs that interfere with their treatment. We investigated primary care physicians’ interest in a model web-based comparative drug pricing resource.

The Physician Payments Sunshine Act Fact Sheet

The Physician Payments Sunshine provisions in the Affordable Care Act require drug and medical device manufacturers to publicly report gifts and payments made to physicians and teaching hospitals.

Toolkit on Conflict of Interest Policy Implementation

This toolkit provides a guide to the process of COI policy development and implementation. The toolkit discusses the importance of making professionalism your central tenet, developing a good process, as well as other key concepts.

Toolkit on Gifts, Meals and Entertainment

In this toolkit, the ways in which gifts create bias and undermine professionalism are discussed, along with widely adopted recommendations for prohibition by medical leaders.

Top Twenty Pay-for-Delay Drugs: How Drug Industry Payoffs Delay Generics, Inflate Prices and Hurt Consumers

This report reveals that these drugs were subject to an industry practice called "pay for delay," in which brand name pharmaceutical companies pay off generic drug manufacturers to keep lower cost equivalents off the market, forcing consumers to pay highe

Toolkit on Speakers Bureaus

Promotional speaking (speakers bureaus) is the practice of pharmaceutical companies recruiting and training physicians to give talks promoting company products. This toolkit recommends a ban to maintain the integrity of patient care and clinical research,

Toolkit on Relations with Sales Representatives

In this toolkit the prevalence and impact of these industry practices are discussed, along with arguments that have been made for and against meeting with sales representatives. Policy solutions and model policies are presented, ranging from exclusion to

Toolkit on Ghostwriting and Name-Lending

This toolkit addresses the practice of fraudulently hiding the true identity of authors in medical research and publishing. Policy and enforcement recommendations, a checklist for preventing this practice, and two model policies are included.

Toolkit on Continuing Medical Education

This toolkit addresses the issue of pharmaceutical and device industry support for continuing medical education. It outlines concerns about the effects of such support on the information that clinicians receive through CME programs and subsequent bias in

Addressing Industry Conflicts-of-Interest at Academic Medical Institutions

Community Catalyst is a partner in a three-year initiative, the Partnership to Advance ConflictFree Medical Education (PACME), launched in 2011 to address the need for improvements in conflict-of-interest standards at the approximately 150 medical schools

Conflict-of-Interest Curriculum Toolkit

This toolkit provides the rationale for teaching about conflict of interest in medical schools and residency programs and a succinct overview of the competencies learners should achieve, along with the theory supporting various educational approaches. It

Conflict of Interest Policy Guide for Medical Schools and Academic Medical Centers

These toolkits are provided to assist leaders, faculty, staff and medical students in successfully adopting and improving policies to address conflicts of interest and interactions with the pharmaceutical and device industries. Policies such as these and

Partnership to Advance Conflict-Free Medical Education

Letter to Secretary Sebelius Regarding Disclosure of Industry Payment to Physicians and Teaching Hospitals

Under the Physician Payments Sunshine Provision, manufacturers of drugs, devices, biologics or medical supplies, or their subsidiaries that sell these products in the United States, must report to Health and Human Services certain payments made to physici

Pew Health Group Report: "After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs"

Community Catalyst Statement on Supreme Court Decision Striking Down Vermont Law Protecting Prescription Records

NLARx Press Release: Supreme Court Overturns Vermont Prescription Records Privacy Law in Sorrell v. IMS Health

Letter in Support of Drug Safety Enhancement Act

Eight national organizations in addition to Community Catalyst sent this letter to all members of the House of Representatives in support of the Drug Safety Enhancement Act of 2011, HR 1483.

Summary of Drug Safety Enhancement Act of 2011, HR 1483

US Pharmacopeia: "USP Verified" Consumer Guide for Vitamins and Supplements

Amicus Brief, filed with the U.S. Supreme Court, in Support of Vermont Law Banning Data Mining

Generic Pharmaceutical Association: Savings Achieved Through the Use of Generic Pharmaceuticals, 2000-2009

New York State's Medicaid Prescriber Education Program

Maine's Academic Detailing Program

Consumer Reports Best Buy Drugs

Consumers Union

National Physicians Alliance

National Legislative Association on Prescription Drug Prices

Project on Information Justice and Intellectual Property

AMSA PharmFree Scorecard

Prescription Policy Choices

Independent Drug Information Services

National Resource Center for Academic Detailing

Council on Foreign Relations: Symposium on Food and Drugs: Can Safety Be Ensured in a Time of Increased Globalization?

Comments on FDA Supply Chain Strategic Priority

Comments of Community Catalyst and six additional organizations on the FDA's draft strategic priority of strengthening the safety and integrity of the global supply chain.

Safety of Over-the-Counter Drugs Fact Sheet

In recent years there have been a number of incidents pointing to the safety concerns of over-the-counter drugs. In 2009, a record 1,742 drugs -- including 50 dietary supplements -- were recalled, four times the number recalled in 2008.1 Many of these inv

Safety of the Prescription Drug Supply Fact Sheet

Drug Safety and Accountability Act of 2010 Fact Sheet

Exposing the Gaps Fact Sheet

Alliace for a Safe Drug Supply: Statement of Principles

Pew Prescription Project: Securing a Safe Drug Supply

Drug Safety and Accountability Act of 2010

News Release on Drug Safety and Accountabilty Act of 2010 from Senator Bennet (D-CO)

Colorado Prescription Coalition Seeks Pharma Marketing Reforms

The Colorado Prescription Coalition this session is building on gains it made last year to promote safe, cost-effective prescribing.  The coalition is supporting the Pharmaceutical Transparency Act (SB 10-126), legislation introduced this session ...

Wisconsin Coalition Looks at Prescriber Education and Pharmaceutical Reforms

A coalition of Wisconsin organizations led by the Coalition of Wisconsin Aging Groups has convened to continue work it began last year to improve prescribing and the quality of care delivered in the state.  The coalition has cooperated with the ch...

Minnesota Prescription Coalition Seeks Prescribing, Marketing Reforms

The Minnesota Prescription Coalition (MPC) was formed in the fall of 2009 as the result of a broad based group of organizations coming together to promote evidence based prescribing and to deal with conflicts of interest issues in medical field.  ...

AARP: Rx Watchdog Report

Consumer Survey

National Coalition for Appropriate Prescribing

National Coalition for Appropriate Prescribing (NCAP) Members

Evidence-Based Prescribing

Physicians and other prescribers need unbiased, systematic, and easily accessible information to help them make the best treatment decisions for patients who rely on them for care. Similarly, both public programs and private insurers need this informat...

Academic Detailing Fact Sheet

The Independent Drug Education and Outreach Act Fact Sheet

Sample Prescription Medications Fact Sheet

Why Small Gifts Matter Fact Sheet

Addressing Cost and Quality: The Physician Payments Sunshine Act

Prescription Record Privacy Act Model Bill

The Case for Disclosure

Pharmaceutical Industry Marketing Fact Sheet

Non-physician Prescribers and Pharmaceutical Industry Interactions

Prescriber Profiling Testimony in Maryland, Dec. 2008

Prescription Data Mining Fact Sheet

GAO report: Better data management, more inspections needed to strengthen FDA's foreign drug inspection program

Comments to FDA on Limitations and Risks of Direct-to-Consumer Advertising

Regulating Industry Payments to Physicians: Identifying & Minimizing Conflicts Of Interest: Fact Sheet

PhRMA Marketing Code on Interactions with Healthcare Professionals: Old vs. New

Prescriber Education Model Legislation

Data Mining Amicus Curiae: IMS Health v. Sorrell

Data Mining and Medicaid Fact Sheet

Comments to FDA on Good Journal Reprint Practices

Advancing Efficient Management and Purchasing of Prescription Drugs

Cost-Effectiveness of Prescriber Education (Academic Detailing) Programs

Prescription Drug and Medical Device Marketing Restrictions and Disclosure Act Model Legislation

Risk with No Benefit: The Marketing of Over-the-Counter Cough and Cold Medications for Children

The Constitutional Battle over State Regulation of Data Mining

Data Mining Amicus Curiae: IMS Health v. Ayotte